Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer (FETCH)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Queensland
-
Coopers Plains, Queensland, Australia, 4108
- Queen Elizabeth II Jubilee Hospital
-
Herston, Queensland, Australia, 4029
- Royal Brisbane and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18-80 years
- Any patient having abdominal surgery (Laparoscopic or open technique) for benign conditions
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients must have adequate:
- Hematologic function: Neutrophils ≥ 1.5 x 109/L and platelets ≥ 100 x 109/L
- Renal function: serum creatinine ≤ ULN or estimated glomerular filtration rate (eGFR) [CKD-EPI Formula] ≥ 60 mL/min
- Hepatic function: serum bilirubin ≤ 1.5 x ULN and AST ≤ 2.5 x ULN and ALT≤ 2.5 x ULN
- Physically able to undergo surgery
- Written informed consent
Exclusion Criteria:
- Confirmed gynaecological malignancy
- Contraindications and/or unfit for Surgery: serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
- Patients who are pregnant or lactating
- Serious illness or medical condition but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (patients with stable AF are eligible), or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with disseminated intra-peritoneal malignancy or suspected ovarian cancer
- HIV positive
- Previous bariatric surgery
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Female Group 2
Females with BMI >30 kg/m2 who are having a hysterectomy for benign conditions
|
|
Females Group 1
Females with BMI <30 kg/m2 who are having a hysterectomy for benign conditions
|
|
Males
2 males with BMI <30 kg/m2 and 2 males with BMI >30 kg/m2
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identify estrogen-response genes in endometrial cancer
Time Frame: Baseline
|
Omental fat will be collected from 6 lean patients, 6 obese patients and 4 controls (male patients) and co-cultured with endometrial cancer cell lines
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Examine how expression of estrogen response genes are altered in obesity
Time Frame: Baseline
|
Compare gene response in tissue from lean and obese individuals
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Donal Brennan, Queensland Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FETCH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.